Abstract
Congress ASCO 2017 and Pembrolitzumab - updated results of KEYNOTE-001, KEYNOTE-024 and cohorts G KEYNOTE-021 and the feasibility of consolidation treatment for inoperable NSCLC stage III.
Congress ASCO 2017 and Pembrolitzumab - updated results of KEYNOTE-001, KEYNOTE-024 and cohorts G KEYNOTE-021 and the feasibility of consolidation treatment for inoperable NSCLC stage III.